The Statistical Fragility of Platelet-Rich Plasma as Treatment for Plantar Fasciitis: A Systematic Review and Simulated Fragility Analysis

Background: Plantar fasciitis (PF) is the most common cause of heel pain and can be a source of extensive physical disability and financial burden. Platelet-rich plasma (PRP) offers a potentially definitive, regenerative treatment modality that, if effective, could change the current paradigm of PF...

Full description

Bibliographic Details
Main Authors: Arjun Gupta BS, Carlos Ortiz-Babilonia BS, Amy L. Xu BS, Davis Rogers MD, Ettore Vulcano MD, Amiethab A. Aiyer MD
Format: Article
Language:English
Published: SAGE Publishing 2022-12-01
Series:Foot & Ankle Orthopaedics
Online Access:https://doi.org/10.1177/24730114221144049
_version_ 1797977829073223680
author Arjun Gupta BS
Carlos Ortiz-Babilonia BS
Amy L. Xu BS
Davis Rogers MD
Ettore Vulcano MD
Amiethab A. Aiyer MD
author_facet Arjun Gupta BS
Carlos Ortiz-Babilonia BS
Amy L. Xu BS
Davis Rogers MD
Ettore Vulcano MD
Amiethab A. Aiyer MD
author_sort Arjun Gupta BS
collection DOAJ
description Background: Plantar fasciitis (PF) is the most common cause of heel pain and can be a source of extensive physical disability and financial burden. Platelet-rich plasma (PRP) offers a potentially definitive, regenerative treatment modality that, if effective, could change the current paradigm of PF care. However, randomized controlled trials (RCTs) on the clinical benefits of PRP for refractory PF offer inconsistent conclusions, potentially because of the broader limitations of using P value thresholds to declare statistical and clinical significance. In this study, we use the Continuous Fragility Index (CFI) and Quotient (CFQ) to appraise the statistical robustness of data from RCTs evaluating PRP for treatment of PF. Methods: RCTs comparing outcomes after PRP injection vs alternative treatment in patients with chronic PF were evaluated. Representative simulated data sets were generated for each reported outcome event using summary statistics. The CFI was determined by manipulating each data set until reversal of significance (α=0.05) was achieved. The corresponding CFQ was calculated by dividing the CFI by the sample size. Results: Of 259 studies screened, 20 studies (59 outcome events) were included in this analysis. From these simulations, the median CFI for all events was 9, suggesting that varying the treatment of 9 patients would be required to reverse trial significance. The corresponding CFQ was 0.177. Studies with reported P value <.05 were more statistically fragile (CFI=10, CFQ=0.122) than studies with reported P value >.05 (CFI=5, CFQ=0.179). Of 36 outcome events reporting lost to follow-up data, 10 events (27.8%) lost ≥9 patients. Conclusion: Our findings suggest that, on average, the statistical fragility of RCTs evaluating PRP for nonoperative PF therapy is at least comparable to that of the sports medicine literature. However, several included studies had concerningly low simulated fragility scores. Orthopaedic surgeons may benefit from preferentially relying on studies with higher CFI and CFQ values when evaluating the utility of PRP for chronic PF in their own clinical practice. Given the importance of RCT data in clinical decision making, fragility indices could help give context to the stability of statistical findings. Level of Evidence: Level I, systematic review.
first_indexed 2024-04-11T05:13:18Z
format Article
id doaj.art-ac48bae720724e778e9c3f406620224b
institution Directory Open Access Journal
issn 2473-0114
language English
last_indexed 2024-04-11T05:13:18Z
publishDate 2022-12-01
publisher SAGE Publishing
record_format Article
series Foot & Ankle Orthopaedics
spelling doaj.art-ac48bae720724e778e9c3f406620224b2022-12-24T15:33:29ZengSAGE PublishingFoot & Ankle Orthopaedics2473-01142022-12-01710.1177/24730114221144049The Statistical Fragility of Platelet-Rich Plasma as Treatment for Plantar Fasciitis: A Systematic Review and Simulated Fragility AnalysisArjun Gupta BS0Carlos Ortiz-Babilonia BS1Amy L. Xu BS2Davis Rogers MD3Ettore Vulcano MD4Amiethab A. Aiyer MD5Department of Orthopaedic Surgery, Rutgers New Jersey Medical School, Newark, NJ, USADepartment of Orthopaedic Surgery, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto RicoDepartment of Orthopaedic Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USADepartment of Orthopaedic Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USADepartment of Orthopaedic Surgery, Columbia University Mount Sinai Medical Center, Miami, FL, USADepartment of Orthopaedic Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USABackground: Plantar fasciitis (PF) is the most common cause of heel pain and can be a source of extensive physical disability and financial burden. Platelet-rich plasma (PRP) offers a potentially definitive, regenerative treatment modality that, if effective, could change the current paradigm of PF care. However, randomized controlled trials (RCTs) on the clinical benefits of PRP for refractory PF offer inconsistent conclusions, potentially because of the broader limitations of using P value thresholds to declare statistical and clinical significance. In this study, we use the Continuous Fragility Index (CFI) and Quotient (CFQ) to appraise the statistical robustness of data from RCTs evaluating PRP for treatment of PF. Methods: RCTs comparing outcomes after PRP injection vs alternative treatment in patients with chronic PF were evaluated. Representative simulated data sets were generated for each reported outcome event using summary statistics. The CFI was determined by manipulating each data set until reversal of significance (α=0.05) was achieved. The corresponding CFQ was calculated by dividing the CFI by the sample size. Results: Of 259 studies screened, 20 studies (59 outcome events) were included in this analysis. From these simulations, the median CFI for all events was 9, suggesting that varying the treatment of 9 patients would be required to reverse trial significance. The corresponding CFQ was 0.177. Studies with reported P value <.05 were more statistically fragile (CFI=10, CFQ=0.122) than studies with reported P value >.05 (CFI=5, CFQ=0.179). Of 36 outcome events reporting lost to follow-up data, 10 events (27.8%) lost ≥9 patients. Conclusion: Our findings suggest that, on average, the statistical fragility of RCTs evaluating PRP for nonoperative PF therapy is at least comparable to that of the sports medicine literature. However, several included studies had concerningly low simulated fragility scores. Orthopaedic surgeons may benefit from preferentially relying on studies with higher CFI and CFQ values when evaluating the utility of PRP for chronic PF in their own clinical practice. Given the importance of RCT data in clinical decision making, fragility indices could help give context to the stability of statistical findings. Level of Evidence: Level I, systematic review.https://doi.org/10.1177/24730114221144049
spellingShingle Arjun Gupta BS
Carlos Ortiz-Babilonia BS
Amy L. Xu BS
Davis Rogers MD
Ettore Vulcano MD
Amiethab A. Aiyer MD
The Statistical Fragility of Platelet-Rich Plasma as Treatment for Plantar Fasciitis: A Systematic Review and Simulated Fragility Analysis
Foot & Ankle Orthopaedics
title The Statistical Fragility of Platelet-Rich Plasma as Treatment for Plantar Fasciitis: A Systematic Review and Simulated Fragility Analysis
title_full The Statistical Fragility of Platelet-Rich Plasma as Treatment for Plantar Fasciitis: A Systematic Review and Simulated Fragility Analysis
title_fullStr The Statistical Fragility of Platelet-Rich Plasma as Treatment for Plantar Fasciitis: A Systematic Review and Simulated Fragility Analysis
title_full_unstemmed The Statistical Fragility of Platelet-Rich Plasma as Treatment for Plantar Fasciitis: A Systematic Review and Simulated Fragility Analysis
title_short The Statistical Fragility of Platelet-Rich Plasma as Treatment for Plantar Fasciitis: A Systematic Review and Simulated Fragility Analysis
title_sort statistical fragility of platelet rich plasma as treatment for plantar fasciitis a systematic review and simulated fragility analysis
url https://doi.org/10.1177/24730114221144049
work_keys_str_mv AT arjunguptabs thestatisticalfragilityofplateletrichplasmaastreatmentforplantarfasciitisasystematicreviewandsimulatedfragilityanalysis
AT carlosortizbabiloniabs thestatisticalfragilityofplateletrichplasmaastreatmentforplantarfasciitisasystematicreviewandsimulatedfragilityanalysis
AT amylxubs thestatisticalfragilityofplateletrichplasmaastreatmentforplantarfasciitisasystematicreviewandsimulatedfragilityanalysis
AT davisrogersmd thestatisticalfragilityofplateletrichplasmaastreatmentforplantarfasciitisasystematicreviewandsimulatedfragilityanalysis
AT ettorevulcanomd thestatisticalfragilityofplateletrichplasmaastreatmentforplantarfasciitisasystematicreviewandsimulatedfragilityanalysis
AT amiethabaaiyermd thestatisticalfragilityofplateletrichplasmaastreatmentforplantarfasciitisasystematicreviewandsimulatedfragilityanalysis
AT arjunguptabs statisticalfragilityofplateletrichplasmaastreatmentforplantarfasciitisasystematicreviewandsimulatedfragilityanalysis
AT carlosortizbabiloniabs statisticalfragilityofplateletrichplasmaastreatmentforplantarfasciitisasystematicreviewandsimulatedfragilityanalysis
AT amylxubs statisticalfragilityofplateletrichplasmaastreatmentforplantarfasciitisasystematicreviewandsimulatedfragilityanalysis
AT davisrogersmd statisticalfragilityofplateletrichplasmaastreatmentforplantarfasciitisasystematicreviewandsimulatedfragilityanalysis
AT ettorevulcanomd statisticalfragilityofplateletrichplasmaastreatmentforplantarfasciitisasystematicreviewandsimulatedfragilityanalysis
AT amiethabaaiyermd statisticalfragilityofplateletrichplasmaastreatmentforplantarfasciitisasystematicreviewandsimulatedfragilityanalysis